drugset / Trial / NCT01534208

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

NCT01534208

Phase 3 Completed 499 enrolled Repros Therapeutics Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

ZA-300 is meant to determine the safety profile of Androxal (enclomiphene citrate) in men with secondary hypogonadism.

Timeline

Start
2012-05
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Androxal Unknown 12.5 mg Oral
Subject Androxal Unknown 25 mg Oral